Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $36.65 million. The enterprise value is -$59.85 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, before market open.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 51.83 million shares outstanding. The number of shares has increased by 17.91% in one year.
| Current Share Class | 51.83M |
| Shares Outstanding | 51.83M |
| Shares Change (YoY) | +17.91% |
| Shares Change (QoQ) | +178.05% |
| Owned by Insiders (%) | 14.04% |
| Owned by Institutions (%) | 13.32% |
| Float | 25.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.15 |
| Forward PS | 0.89 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.20
| Current Ratio | 2.20 |
| Quick Ratio | 2.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36.48 |
Financial Efficiency
Return on equity (ROE) is -908.28% and return on invested capital (ROIC) is -191.61%.
| Return on Equity (ROE) | -908.28% |
| Return on Assets (ROA) | -26.26% |
| Return on Invested Capital (ROIC) | -191.61% |
| Return on Capital Employed (ROCE) | -56.64% |
| Revenue Per Employee | $496,938 |
| Profits Per Employee | -$913,891 |
| Employee Count | 64 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.11% in the last 52 weeks. The beta is -0.05, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -29.11% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 36.22 |
| Average Volume (20 Days) | 990,412 |
Short Selling Information
The latest short interest is 6.16 million, so 11.88% of the outstanding shares have been sold short.
| Short Interest | 6.16M |
| Short Previous Month | 5.25M |
| Short % of Shares Out | 11.88% |
| Short % of Float | 24.57% |
| Short Ratio (days to cover) | 10.70 |
Income Statement
In the last 12 months, XLO had revenue of $31.80 million and -$58.49 million in losses. Loss per share was -$1.13.
| Revenue | 31.80M |
| Gross Profit | 53.42M |
| Operating Income | -43.78M |
| Pretax Income | -58.49M |
| Net Income | -58.49M |
| EBITDA | -42.18M |
| EBIT | -43.78M |
| Loss Per Share | -$1.13 |
Full Income StatementBalance Sheet
The company has $103.76 million in cash and $7.26 million in debt, giving a net cash position of $96.50 million or $1.86 per share.
| Cash & Cash Equivalents | 103.76M |
| Total Debt | 7.26M |
| Net Cash | 96.50M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | -8.10M |
| Book Value Per Share | -0.16 |
| Working Capital | 67.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.15 million and capital expenditures -$429,000, giving a free cash flow of -$17.58 million.
| Operating Cash Flow | -17.15M |
| Capital Expenditures | -429,000 |
| Free Cash Flow | -17.58M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
Gross margin is 167.97%, with operating and profit margins of -137.64% and -183.90%.
| Gross Margin | 167.97% |
| Operating Margin | -137.64% |
| Pretax Margin | -183.90% |
| Profit Margin | -183.90% |
| EBITDA Margin | -132.63% |
| EBIT Margin | -137.64% |
| FCF Margin | n/a |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.91% |
| Shareholder Yield | -17.91% |
| Earnings Yield | -159.57% |
| FCF Yield | -47.96% |
Analyst Forecast
The average price target for XLO is $2.00, which is 182.81% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.00 |
| Price Target Difference | 182.81% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | -15.63% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
